Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scandi Standard –Third quarter presentation

Scandi Standard will publish its report for the third quarter of 2022 on Thursday, 27th of October 2022, at 07.30 CET.   Conference call at 08.30 CETThe Company will host a conference call for the financial community at 08.30 CET on the same day. The conference call will be hosted by Jonas Tunestål, CEO, and Julia Lagerqvist, CFO.   Dial-in numbers: United Kingdom 0800 640 6441United Kingdom (Local) 020 3936 2999Sweden: 0200 123 717Sweden (Local): 010 884 80 16USA: 1 855 9796 654USA (local): 1 646 664 1960All other locations +44 20 3936 2999   Participant

Medical devices – a rapidly growing market

One of Lesjöfors’ core markets is growing rapidly – the global medical devices market. Reports show that the market is expanding worldwide. Lesjöfors is a qualified supplier of components to the sector and can meet the high demands of hygiene and quality.In a market analysis from Fortune Business Insights , the market for medical devices is projected to grow from USD 495 billion in 2022 to USD 718 billion in 2029. Key drivers of the market are the rising prevalence of chronic disorders, increased access

BioStock: Mendus nears late-stage development with cancer relapse vaccine

Tumour recurrence is the underlying cause of the majority of cancer deaths worldwide. Tackling the issue is immuno-oncology company Mendus with the development of relapse vaccine DCP-001. Encouraging data has come from both a phase II trial in acute myeloid leukeamia and a phase I trial in ovarian cancer, which has been accompanied by funding by the European Commission as well as landing a manufacturing agreement aimed at late-stage and commercial production of DCP-001. Key survival data updates from the phase II study in AML are expected during Q4 this year.Read the article at biostock.se:

BioStock: Founder and CTO on Iconovo’s journey

The inhalation company Iconovo was founded in 2013 by several people with extensive experience in the development and commercialization of inhalation drugs. Today, the company has four patent-protected inhalation platforms, nine development agreements with international pharma companies and over 30 employees. BioStock interviewed Orest Lastow, co-founder and CTO, about Iconovo’s journey from the start to now.Read the full article at biostock.se:https://www.biostock.se/en/2022/10/founder-and-cto-on-iconovos-journey/ This is a press release from BioStock - Connecting Innovation & Capital.

Groundbreaking research on the impact of microplastic pollution in oceans awarded the Volvo Environment Prize 2022

Small pieces of plastics are widely spread all over the world's oceans and ingested by living creatures. Microplastics are found in zooplankton, fish, seabirds, whales, seals, and also in humans. Yet, the long-term effects of this plastic pollution threat are still largely unknown. Three scientists, Richard Thompson, Tamara Galloway, and Penelope Lindeque, that have conducted ground-breaking research in understanding the impact of microplastics on humans and the environment are this year's laureates of the Volvo Environment Prize .With the help of winds

Valmet to deliver sixth tissue production line to Papel San Francisco in Mexico

Valmet Oyj’s press release on October 24, 2022 at 11:00 a.m. EESTValmet will supply an Advantage DCT 100TS tissue production machine to Papel San Francisco in Mexico. The new machine will be installed at the company's mill in Mexicali and the start-up is planned for the first half of 2024. The order is included in Valmet's orders received of the third quarter 2022. The value of the order will not be disclosed. The new tissue line will fulfill Papel San Francisco's need of new capacity for standard tissue products. Valmet has previously delivered five tissue machines to the company.

TOMRA - Contemplating NOK senior unsecured green bond issuance

TOMRA Systems ASA, rated A- (stable) by Scope, has mandated DNB Markets and Nordea as Joint Lead Managers to arrange a virtual investor meeting on 25 October 2022 where the company and the newly established green bond framework will be presented. Subject to market conditions, one or several NOK denominated senior unsecured green bond issues with expected tenor(s) of 3-5 years may follow. DNB Markets and Nordea acted as Joint Structuring Advisors of TOMRA’s new green bond framework which has obtained a “Dark Green” shading and governance score “Good” from Cicero (Shades of Green). The

Buybacks of shares by H&M during week 42, 2022

Between 17 October 2022 and 21 October 2022 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 1,247,000 own B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the SEK 3.0 billion share buyback programme that H&M announced on 29 June 2022. The share buyback programme, which runs between 29 June 2022 and 30 November 2022, is being carried out in accordance with Regulation (EU) No 596/2014 on market abuse (the Market Abuse Regulation – MAR) and Commission Delegated

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 218 - 24 OCTOBER 2022  In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 158/22. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor

Company Announcement No. 115, 2022 – Debtor composition in Nordea Kredit (CK 92)

Monthly information on debtor composition in Nordea Kredit published in order to comply with the Transparency Directive's disclosure requirements. Nordea Kredit hereby publishes monthly data on debtor composition of all callable bond series. The information is subject to disclosure requirements in the Securities Trading Act § 27a section 1.The information is also published in the usual way via the Copenhagen Stock Exchange / OMX.   Nordea Kredit Realkreditaktieselskab   Klaus Johnbeck Phone : +45 55 47 05 11

DAMPSKIBSSELSKABET NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 217 - 24 OCTOBER 2022   On 18 August 2022, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 18 August 2022 up to and including no later than 1 November 2022. For details, please see announcement no. 158 of 18 August 2022.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 40 million (approximately DKK 290

Announcement of extension of offer period

Ahlsell Danmark ApS ("Ahlsell") extends the offer period of the offer to the holders of approx. 24.51% af the shares in Sanistål A/S ("Sanistål").On 24 May 2022, Ahlsell announced that Ahlsell had entered into conditional share purchase agreements with Danske Bank A/S, Nordea Bank Abp, Jyske Bank A/S and Nykredit Bank A/S (the "Major Shareholders") to acquire approximately 75.49% of the shares in Sanistål at a price of DKK 58 per share. In addition, Ahlsell announced that they would make a recommended conditional voluntary public offer (the "Offer") to purchase the remaining

Scania presents new and empowered solutions at Bauma

As the Bauma trade fair for construction starts in Munich on 24 October, Scania will be there to showcase the newly launched inline engine platform for the first time.Scania brings several products to the fair, among them is the Next Generation 13-litre DC13 engine for industrial operations and power generation. On display in the stand will also be the E-machine and battery for electrified power solutions. Scania is known to be a reliable supplier of power solution engines and now our products are even more sustainable. Scania’s Connected Services are not only designed to ensure you get top

Scientific article published about ExpreS2ion’s human candidate HER-2 virus-like particle vaccine, ES2B-C001

Hørsholm, Denmark, October 24, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal Biomedicines published an article about the breast cancer vaccine candidate ES2B-C001 titled “Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine”.Abstract excerpt: “…ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.” This publication is a result of the

Publishing of Caverion Corporation's Interim Report for January−September 2022 on 3 November 2022

Caverion Corporation Investor News 24 October 2022 at 10.00 a.m. EESTPublishing of Caverion Corporation's Interim Report for January−September 2022 on 3 November 2022 Caverion Corporation's Interim Report for January− September 2022 will be published on Thursday, 3 November 2022, at approximately 8:00 a.m. (Finnish Time, EET). The stock exchange release and presentation materials in Finnish and in English will be published at that time on the company's website at www.caverion.com/investors. News conference for investors and media Caverion will hold a news conference on the Interim

NextCell cell therapy shows long-term effect in two independent diabetes studies "ProTrans-Repeat" and "ProTrans-Obs" – live presentation

NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broadcast live via Nyhetsbytrån Direkt, link https://youtu.be/Y9BSbt31tqc.· Thursday, October 27, CET 3:00 pm · https://youtu.be/Y9BSbt31tqc Below follows an update on the Company's completed and ongoing clinical trials with the drug candidate ProTrans, which has been developed for type-1 diabetes,

BioStock: Curasight takes the next step in the two new indications

So far, 2022 has been a rather decisive year for Copenhagen based Curasight. After adding head and neck cancer and neuroendocrine tumours to the list of focus indications for drug candidate uTRACE, the time has now come to pursue them also for uTREAT. The company announced recently the start of preclinical studies in both the indications, further building on its theranostic strategy.Read the full article at biostock.se: https://www.biostock.se/en/2022/10/curasight-takes-the-next-step-in-the-two-new-indications/ This is a press release from BioStock - Connecting Innovation & Capital.

Interim report January–September 2022: SLP’s portfolio consists of sustainable logistics properties with stable financing

Since the company started, SLP’s business model has built stable operations. The emphasis on logistics properties with a focus on sustainability, long term relationships with strong tenants and secured bank financing gives the company security amid continued market uncertainty.· Rental income increased by 59%, amounting to SEK 301 m (190). · Profit from property management excluding listing expenses increased by 65% and amounted to SEK 169 m (103). · Profit for the period was impacted by non-recurring costs of SEK 25 m (0) related to the IPO. · Earnings per share after dilution

Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST)-Therapist Companion

Copenhagen, Denmark, October 24, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Commercial launch in Denmark will be November 1, 2022 · Adaptation of a UK product version for the United Kingdom starts November 1[st] in collaboration with a key UK CST researcher, the exact launch timing will be announced later.Brain+ (BRAINP), a pioneer in the development of digital therapeutics for Alzheimer’s disease and dementia, will open for sales of its first digital dementia product, Cognitive Stimulation Therapy (CST)-Therapist Companion, in Denmark on November 1, 2022. This is fully in

Crunchfish reach important milestone in the project with Reserve Bank of India

Crunchfish’s project for Offline Retail Payments together with HDFC Bank and one additional Indian bank has reached an important milestone by completing the integration of Crunchfish Digital Cash SDK into both Payer and Merchant apps. This milestone was reached before the Diwali holiday and confirms that the project is on track to start the pilot with Reserve Bank of India in mid-December. Crunchfish  in partnership with HDFC Bank  and one additional Indian bank are working together to demonstrate and pilot Offline Retail

Latour invests in SenseNode AB

Investment AB Latour (publ) has, through its subsidiary Latour Future Solutions AB, signed an agreement to invest in SenseNode AB (“SenseNode”). SenseNode has developed a complete IoT-solution with associated SaaS-platform for energy efficiency in all types of industries. The company offers energy monitoring, energy mapping, power optimization and energy efficiency, with associated automatic reports and alarm functions. The business was founded in 2013 and is headquartered in Lund with 8 employees. "SenseNode's solutions are within one of our investment areas – sustainable energy

Wulff Group Plc’s Interim Report for January 1 – September 30, 2022

INTERIM REPORT | OCTOBER 24, 2022 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Interim Report for January-September 2022. Wulff Group’s Interim Report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website www.wulff.fi . Operating profit increased due to profitability measures 1.7.–30.9.2022 BRIEFLY · Net sales totalled EUR 24.0 million (24.2), decreased by 1.0% · EBITDA and comparable EBITDA were EUR 1.7 million (1.7) · Operating profit (EBIT) and comparable operating profit (

AirForestry puts forestry and technical innovation in focus on prestigious list

AirForestry , which develops high-capacity drones for forest thinning, announces today that the company has been named as one of a total of 33 technological innovation companies by the heavy technology Swedish magazine Ny Teknik's 33-list 2022. The companies on the 33 list represent many different technology industries but, according to Ny Teknik, they have one important thing in common — a strong proprietary technological innovation with the potential to change its industry and achieve international success. -Getting a place on Ny Teknik's list of the

Sigrid Therapeutics appoints internationally established consumer industry executive Mattias Ankarberg as Chairman

Company aims to capitalize on new health and wellbeing market opportunities for SiPore® supplements Stockholm, Sweden October 24[th] October, 2022. Sigrid Therapeutics, a Swedish consumer health tech company, today announced that it has appointed Mattias Ankarberg as Chairman of the Board. Mattias has a long and successful career in the international retail and consumer goods industry. He is currently CEO of publicly listed Byggmax Group and board member of Thule Group, and has previously spent many years with H&M, most recently as Global Head of Sales & Marketing, and with McKinsey &

There are no items matching the current filter
There are no more items matching the current filter
Back to top